Toppy, E. v. Passage Bio, Inc

2022 Pa. Super. 190, 285 A.3d 672
CourtSuperior Court of Pennsylvania
DecidedNovember 9, 2022
Docket24 EDA 2021
StatusPublished
Cited by22 cases

This text of 2022 Pa. Super. 190 (Toppy, E. v. Passage Bio, Inc) is published on Counsel Stack Legal Research, covering Superior Court of Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Toppy, E. v. Passage Bio, Inc, 2022 Pa. Super. 190, 285 A.3d 672 (Pa. Ct. App. 2022).

Opinion

J-A15025-21

2022 PA Super 190

ERIC TOPPY IN THE SUPERIOR COURT OF PENNSYLVANIA Appellant

v.

PASSAGE BIO, INC.

Appellee No. 24 EDA 2021

Appeal from the Order Entered November 25, 2020 In the Court of Common Pleas of Philadelphia County Civil Division at No: 200400905

BEFORE: BOWES, J., STABILE, J., and MUSMANNO, J.

OPINION BY STABILE, J.: FILED NOVEMBER 9, 2022

In this employment dispute, Appellant, Eric Toppy, filed a five-count

complaint against Appellee, Passage Bio, Inc., alleging that Appellee breached

a settlement agreement that resolved Appellant’s wrongful termination claims

against Appellee. Appellee filed preliminary objections in the nature of

demurrers asserting, inter alia, that the parties never entered a binding

settlement agreement. The trial court sustained Appellee’s preliminary

objections and dismissed the complaint with prejudice. Appellant appeals

from the order of dismissal. We affirm in part and reverse in part. We reverse

the dismissal of Appellant’s claims for breach of the settlement agreement and

violation of the Wage Payment Collection Law (“WPCL”), 43 P.S. §§ 260.1—

260.13. We affirm the dismissal of Appellant’s claims for unjust enrichment,

fraudulent misrepresentation and negligent misrepresentation. J-A15025-21

Appellant’s complaint alleges the following. Appellee is an emerging

growth company engaged in the development of gene therapies for the

treatment of rare central nervous system diseases. In April 2019, based on

his prior employment in the health care industry and his relationships with

rare disease patient organizations, Appellee hired Appellant as Vice President

of Patient Engagement and Market Access. As compensation, Appellee agreed

to pay Appellant an annual salary of $260,000 and a bonus targeted at 25%

of his base salary. Appellee also granted Appellant 448,623 stock options

which were to vest over the ensuing four years.

In October 2019, while Appellant was on a business trip for Appellee in

Europe, Appellant’s supervisor, Ms. Quigley, sent Appellant an e-mail stating

that she intended to terminate his employment. On his return, Appellant met

with Appellee’s general counsel, who told him that his employment was at an

end effective October 25, 2019. Having consulted and retained counsel,

Appellant then asserted1 three employment-related claims for relief against

Appellee: (1) disability discrimination; (2) misrepresentation related to the

forfeiture of the 448,623 stock options he had been granted; and (3)

defamation related to pejorative comments that Quigley made about him to

third parties.

____________________________________________

1 Although the complaint is not clear on this point, it appears from context that Appellant first asserted these claims in private correspondence to Appellee as opposed to the filing of a civil action in the court of common pleas.

-2- J-A15025-21

Appellant and Appellee agreed to mediate his claims before Patricia

McInerney, a former common pleas judge. Complaint, ¶¶ 2, 4. On January

30, 2020, the mediation took place. Id. at ¶ 25. The parties reached

agreement on two of the three settlement terms that Appellant proposed,

namely payment by Appellee of eight months of Appellant’s annual salary and

a 25% bonus pro-rated for eight months. Id. at ¶ 26. What remained

unresolved was the number of shares of common stock Appellee agreed to

issue to Appellant in exchange for his 448,623 stock options.2 Id. at ¶ 27.

Settlement negotiations continued over the weekend regarding the number of

shares of stock to be issued to Appellant. Id. at ¶ 28. On Monday, February

3, 2020, Appellee agreed to issue Appellant 150,000 shares of common stock.

Id.

On February 3, 2020, Judge McInerney sent an e-mail to Appellant’s

counsel, Harold Goodman that stated as follows:

I just got out of a meeting and Susan has replied accepting your proposal:

I just heard back from my client. They agree to the terms [Appellant’s counsel] suggested (150,000 ____________________________________________

2 While stock options “take many forms and have assorted conditions,” Marchlen v. Township of Mt. Lebanon, 746 A.2d 566, 570 n.9 (Pa. 2000), a stock option is, generally speaking, a benefit given by a company to an employee to purchase company stock at a discount or fixed price. Stock shares, on the other hand, represent fractional ownership of an issuing company. Guarantee Trust and Safe Deposit Co. of Mt. Carmel v. Tye, 196 A. 618, 620 (Pa. Super. 1938) (share of stock in business corporation is “one of the whole number of equal parts into which the capital stock of a trading company or corporation is or may be divided”).

-3- J-A15025-21

shares, 8 months’ severance, 25% bonus pro-rated for 8 months, etc.), with two small tweaks:

1. They want to add Lysogene to the list of companies where [Appellant] cannot work (the others are Axovant and Prevail Therapeutics).

2. Regarding the letter of reference, Steve Squinto is willing to state something like Eric’s role changed and he wanted to leave so that he could continue to work in patient engagement. He does not want to address Eric’s performance as he did not supervise Eric and obviously, Eric’s supervisor was critical of his performance.

They also wanted me to make clear that this is their final position.

Id., ex. 1. Nothing in this email stated or suggested that the stock would be

subject to a pre-IPO (initial public offering) reverse stock split. The complaint

alleged that the email constituted an agreement because it resolved the final

issue between the parties. Id. at ¶ 28 (“Following discussions over the

weekend, the parties reached agreement on that remaining issue [the number

of shares of common stock]. Specifically, as reflected in the attached Monday,

February 3, 2020 e-mail from Judge McInerney, [Appellee] agreed with

[Appellant’s] counsel to issue him 150,000 shares of its Common Stock”).

On February 12, 2020, counsel for Appellee sent Appellant’s counsel a

draft settlement agreement and release to review. The draft accurately

described the severance and bonus payments that Appellant would receive.

The draft stated that Appellee would issue Appellant 150,000 shares of its

Common Stock, but it added in a vague parenthesis that the number “may be

adjusted by stock splits, stock combinations, recapitalizations or the like.” Id.

-4- J-A15025-21

at ¶ 31. Unbeknownst to Appellant at that time, Appellee already intended to

authorize a pre-IPO reverse split3 of its common stock. Id. at ¶ 32. Appellee

was aware of this internal decision at the time of the mediation before Judge

McInerney (January 30, 2020) and on the day it agreed to issue Appellant

150,000 shares of its common stock (February 3, 2020). Id. at ¶ 33. Despite

that, Appellee never said anything to Appellant about the reverse stock split

until more than two weeks later. Id. at ¶ 34. On February 18, 2020, counsel

for Appellee informed Appellant’s counsel that four days earlier (February 14,

2020), Appellee’s Board of Directors had met and authorized a 4.43316

reverse split of its common stock. Id. No notice of that meeting was sent to

Appellant or his counsel. Id. at ¶ 36. In effect, without Appellant’s

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Schnizer, A. v. Crafted Supply Company, LLC
Superior Court of Pennsylvania, 2026
Cobb, A. v. Tesla, Inc.
Superior Court of Pennsylvania, 2026
Fabian, J. v. The Pennsylvania State University
Superior Court of Pennsylvania, 2026
Yaffe, C. v. Gushner, K.
Superior Court of Pennsylvania, 2026
Yaffe, R. v. Gushner, K.
Superior Court of Pennsylvania, 2026
Glass, J. v. Gushner, K.
Superior Court of Pennsylvania, 2026
Green, R. v. John Berg Memorial
Superior Court of Pennsylvania, 2025
Klimenko, A. v. Denaburg, D.
Superior Court of Pennsylvania, 2025
Toppy, E. v. Passage Bio
Superior Court of Pennsylvania, 2025
GNS Enterprises v. AMA Ridge, LLC
Superior Court of Pennsylvania, 2025
Giordano, M. V. Ashfield Healthcare
Superior Court of Pennsylvania, 2025
KNUEVEN v. LYSTEN, LLC
E.D. Pennsylvania, 2025
Durst, R. v. Marom Gerritt, II, L.P.
Superior Court of Pennsylvania, 2025
Eric Daimler v. Chris Moehle
Third Circuit, 2025
Doe, J. v. DePaul USA Inc.
Superior Court of Pennsylvania, 2025

Cite This Page — Counsel Stack

Bluebook (online)
2022 Pa. Super. 190, 285 A.3d 672, Counsel Stack Legal Research, https://law.counselstack.com/opinion/toppy-e-v-passage-bio-inc-pasuperct-2022.